Company intelligence / Profile preview

Accent Foods

Lexington, Massachusetts, USA

Ownership: Private
Employees: ~75
Development stage: Other

Overview

Accent Therapeutics is a biopharmaceutical company pioneering the development of small molecule precision cancer therapies by targeting RNA-modifying proteins (RMPs). The company's platform focuses on the "epitranscriptome," identifying RMPs that play critical roles in cancer cell survival and progression. Their lead programs include inhibitors of DHX9 and KIF18A, aimed at treating various solid tumors with high unmet needs. By leveraging deep expertise in RNA biology and drug discovery, Accent aims to deliver transformative treatments for patients with genetically defined cancers. The company is currently advancing its lead DHX9 inhibitor through Phase 1 clinical trials.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

AstraZeneca

Beyond the preview

Go deeper on Accent Foods.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accent Foods.

Explore the full profile